Continuous Manufacturing Market In Pharmaceuticals & Biopharmaceuticals Opportunities and Challenges

The global continuous manufacturing market in pharmaceuticals and biopharmaceuticals size is expected to expand at a CAGR of 13.85%

The global Continuous Manufacturing Market In Pharmaceuticals And Biopharmaceuticals size is expected to reach USD 2.3 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 13.85% from 2021 to 2027. Although batch manufacturing is the dominant mode of product development within the pharma and biopharma industry, the companies have begun shifting their focus toward continuous manufacturing (CM). The key drivers for the transition from batch to continuous manufacturing include drug shortage, more stringent requirements for consistent quality, the need for reduced processing costs, and the demand for higher and improved productivity.

Regulatory authorities are increasingly supportive of this therapeutic development model. They are encouraging the adoption of CM through releasing drafts and guidelines. Moreover, the presence of communities and organizations that are devoted to the commercialization of this market within the pharma and biopharma sector is driving the revenue. CCP Summit 2020 is one of such summits that is engaged in exploring scientific and technological advancements to address the technology challenges and accelerate upfront investment in the market.

In addition, the growing demand for biosimilars and an ever-increasing pressure for reducing drug development costs have driven the interest of biopharma players in this space. With a plethora of research activities available on making individual unit operations continuous, studies are also conducted to explore the possibility of a continuous end-to-end development process. Ongoing research efforts in this area are anticipated to greatly favor the revenue growth in the coming years.

Based on mode, in-house pharmaceutical companies are anticipated to witness lucrative growth in the coming years owing to the shift of well-established pharma players toward the continuous manufacturing market. On the basis of scale, the clinical and preclinical scale manufacturing segments collectively captured a significant revenue share in 2020 owing to the easy integration of systems and a high number of ongoing R&D activities.

North America led the global market in 2020. This is attributed to the presence of key technology developers as well as high R&D expenditure in drug development by the end-users in the U.S. Key players are implementing various strategies to strengthen their product offerings and offer diverse technologically advanced products to accelerate therapeutics development.

Request a free sample copy or view report summary: Continuous Manufacturing Market In Pharmaceuticals & Biopharmaceuticals Report

Continuous Manufacturing Market In Pharmaceuticals & Biopharmaceuticals Report Highlights

• In terms of therapeutics type, the pharmaceutical/small molecules segment dominated the market in 2020 owing to high technology penetration in this segment. The biopharmaceutical/large molecules segment is anticipated to witness lucrative growth owing to increasing investment in facility expansion to integrate CM systems
• On the basis of application, finished product manufacturing led the market in 2020 owing to the established use of CM in finished product development due to the commercial cost and time-saving advantages of technology
• By formulation, solid formulation dominated the market in 2020 owing to the maximum adoption of CM methodologies in solid drug production
• Based on mode, the contract segment led the market in 2020 due to the ongoing demand, coupled with the increasing popularity of contract services. The increasing investment in biosimilars production is expected to spur the use of CM technology within contract manufacturing organizations
• By product, semi-continuous systems accounted for the maximum revenue share in 2020 owing to the increasing adoption of a hybrid model of manufacturing within small to medium-sized drug developers as well as major pharma companies